MB MAINLINE BIOSCIENCES
Live / Applied — Statement of use — response to non-final action entered (as of 03 Mar 2026)
What this means for you
Not registered yet, but its 18 Nov 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97683391
- Mark type
- Design + words
- Filed
- 18 Nov 2022
- Published for opposition
- 26 Nov 2024
- Attorney of record
- Don D. Cha
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention of cancer or tumor; Pharmaceutical preparations for the treatment and prevention of cancer or tumor; Pharmaceutical preparations for the treatment of cancer or tumor; Pharmaceutical preparations for cancer or tumor; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer or tumor
Owner
- Mainline Biosciences (Shanghai) Co., Ltd., Lingang, Shanghai, CN
- Mainline Biosciences (Shanghai) Co., Ltd., Lingang, Shanghai, CN
Prosecution history
- 03 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Dec 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 01 Dec 2025 — NON-FINAL ACTION E-MAILED
- 01 Dec 2025 — SU - NON-FINAL ACTION - WRITTEN
- 14 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 07 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 07 Jul 2025 — NON-FINAL ACTION E-MAILED
- 07 Jul 2025 — SU - NON-FINAL ACTION - WRITTEN
- 30 May 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 07 Mar 2025 — USE AMENDMENT FILED
- 30 May 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL